WithdrawnPHASE2, PHASE3NCT01452295
Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion
Studying Acute liver failure
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vital Therapies, Inc.
- Principal Investigator
- Robert A AshleyVital Therapies, Inc.
- Intervention
- ELAD (Extracorporeal Liver Assist System)(drug)
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2010 – 2012
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01452295 on ClinicalTrials.govOther trials for Acute liver failure
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07409259PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver FailureThird Affiliated Hospital, Sun Yat-Sen University
- ENROLLING BY INVITATIONNANCT06987604Continuous Renal Replacement Therapy Intensity in HyperammonemiaHospital de Clinicas de Porto Alegre
- RECRUITINGNANCT06831643Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver FailureInstitute of Liver and Biliary Sciences, India
- ACTIVE NOT RECRUITINGNANCT06872372Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver FailureLahore General Hospital
- RECRUITINGNCT06908746Efficacy and Safety of Citrate Anticoagulation in CRRT for Patients With Liver Failure/DysfuncTION, the CAUTION Trial! A Retrospective Study on Etiology of Liver Failure and Their ComplicationsUniversity Hospital, Antwerp
- ENROLLING BY INVITATIONNCT06893042Clinical Study of Pediatric Acute Liver FailureFansen Zeng
- RECRUITINGNANCT07329036ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLFInstitute for Clinical and Experimental Medicine
- RECRUITINGPHASE1, PHASE2NCT05989958The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver FailureHexaell Biotech Co., Ltd.